Endocrinology
Conference Coverage
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
News
At 18 months, much still unknown about diabetes and COVID-19
News
FDA approves first once-weekly growth hormone for children
The heiGHt trial demonstrated noninferiority of lonapegsomatropin to somatropin daily injections.
Conference Coverage
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its...
Conference Coverage
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies...
Conference Coverage
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection...
News
U.S. kidney transplants grow in number and success
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
News
US Preventive Services Task Force lowers diabetes screening age for overweight
News
SGLT2 inhibitor use rising in patients with DKD
News
FDA approves rapid-acting insulin, Lyumjev, for pump use
Approved for diabetes treatment last year, it’s the second ultra-rapid-acting insulin approved for use in insulin delivery devices.